Evidence map›Paper›PMID 20977453›Full record

ArticleBritish journal of pharmacology2010

Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.

Tao Yang, Brian F McBride, Brenda F Leake, Richard B Kim, Dan M Roden

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Tao YangOates Institute for Experimental Therapeutics, Departments of Pharmacology and Medicine, University Medical Center, Vanderbilt University School of Medicine, 2215-B Garland Avenue, Nashville, TN 37232-0575, USA. tao.yang@vanderbilt.edu
Brian F McBride
Brenda F Leake
Richard B Kim
Dan M Roden
Vanderbilt University Medical Center · USWestern University · CA

Funding

PHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8M
Transcriptional remodeling in cardiac arrhythmiasP01HL046681 · NHLBI · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L. · 1992 to 2006
$8.1M
MODULATION OF CARDIAC REPOLARIZATIONR01HL049989 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 1994 to 2015
$5.2M
NHLBI NIH HHS HL46681NHLBI NIH HHS HL49989NHLBI NIH HHS P01 HL046681NHLBI NIH HHS R01 HL049989NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U01HL65962
6 · The paper itself

Abstract

background and purposeA common site for drug binding on voltage-gated ion channels is at the interior face of the channel pore. In this study, we tested the hypothesis that the extent of drug block of the human cardiac KCNA5 (K(v) 1.5) channel underlying the atrial-specific, ultra-rapidly activating, delayed K(+) current (I(Kur) ) is modulated by the drug uptake and efflux transporters encoded by organic cation transporter 1 (OCTN1) and multiple drug-resistant gene 1 (MDR1) and expressed in human heart. EXPERIMENTAL APPROACH: Drug block of KCNA5 was assessed in Chinese hamster ovary cells transiently transfected with KCNA5 alone or in combination with the OCTN1 or MDR1 transporter construct, as well as in an MDR1 stably expressed cell line. KEY

resultsCo-expression of OCTN1 significantly facilitated block by quinidine (10 µM), verapamil (20 µM), propafenone (5 µM) and clofilium (30 µM). Further evidence of drug transport modulating drug block was the finding that with OCTN1, block developed faster and only partially washed-out, and that block potentiation was prevented by cimetidine, an inhibitor of OCTN1. MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate). Block was restored by reversin-205 (10 µM, an MDR1 inhibitor). MDR1 did not affect KCNA5 inhibition by KN-93 (1 µM), a blocker acting on the outer mouth of the channel pore. CONCLUSIONS AND IMPLICATIONS: The extent of drug block of KCNA5 can be modulated by drug uptake and efflux transporters. These data provide further support for the idea that modifying intracellular drug concentrations could modulate the effects of blocking ion channels in patients.

Indexed as

AnimalsAnti-Arrhythmia AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Binding SitesBiological TransportCell LineCHO CellsCricetinaeCricetulusGene Expression RegulationHumansKv1.5 Potassium ChannelOrganic Cation Transport ProteinsProtein BindingSwineABCB1 protein, humanAnti-Arrhythmia AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Kv1.5 Potassium ChannelOrganic Cation Transport ProteinsSLC22A4 protein, humanSymporters

Identifiers

PMID20977453
PMCPMC2998684
OpenAlexW1833428816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.